CUMBERLAND PHARMACEUTICALS INC — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
On July 1, 2026, Cumberland closed a $100 million strategic transaction with Apotex Health, divesting its commercial brands and U.S. business. The company retained a clinical-stage pipeline focused on ifetroban, now pursuing FDA approval for DMD cardiomyopathy via NDA submission with rolling review granted. Q3 2026 net income was $77.8M (largely from $81.1M gain on divestiture); cash increased to $80.6M from $11.4M at year-end 2025.
Why this rating
Transformational shift: $100M proceeds = 3.4× company's market cap; divested entire commercial operation; refocused on pipeline. Major liquidity and strategic repositioning for ~$29M market-cap firm.
Tradability signal
NO TRADE
No trade: positive news with only +0.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -1.05% over 4 hrs, n=25). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $5.30 ▼ 0.19% | at our read · unknown $5.31 | +10 min · unknown $5.59 ▲ 5.27% | +30 min · unknown $5.87 ▲ 10.55% | +1 hr · unknown $6.18 ▲ 16.38% | +4 hrs · unknown $6.14 ▲ 15.63% |
The stock had already moved +0.19% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.